

Protalix BioTherapeutics, Inc.
Form 8-K
October 19, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): October 19, 2015

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida	001-33357	65-0643773
(State or other jurisdiction		(IRS Employer
of incorporation)	(Commission File Number)	Identification No.)

Item 8.01. Other Events

On October 19, 2015, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing positive long term data from the 0.2mg, or lowest dose, of the Company’s phase I/II dose ranging clinical trial of PRX-102 for the treatment of Fabry disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated October 19, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: October 19, 2015 By: /s/ Moshe Manor
Name: Moshe Manor
Title: President and
Chief Executive Officer